NCT02302833View on ClinicalTrials.gov

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 17, 2015

Primary Completion Date

November 12, 2024

Study Completion Date

November 12, 2024

Conditions

Locally Advanced ParagangliomaMetastatic Adrenal Gland PheochromocytomaMetastatic ParagangliomaRegional Adrenal Gland PheochromocytomaUnresectable Adrenal Gland PheochromocytomaUnresectable Paraganglioma

Interventions

DRUG

Cabozantinib S-malate

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02302833 - Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery | Biotech Hunter | Biotech Hunter